<DOC>
	<DOCNO>NCT00379418</DOCNO>
	<brief_summary>AIR STUDY TITLE : Anti-Ischemic effect Abciximab ( Reopro ) PATIENT POPULATION : Patients undergo PCI ( interventional procedure place small stent/metallic tube keep narrowed artery heart open ) either stable statin dose statin . Statin= cholesterol lower drug ( ie , lipitor , zocor ) . INTERVENTION : Heparin vs. heparin + abciximab PCI PURPOSE : Measure effect abciximab special heal blood stem cell ( EPC's-Endothelial Progenitor Cells ) , inflammation , oxidative stress microvascular blood flow . PATIENT ASSESSMENT : 1 . 50ccs blood draw day 1 ( sheath ) , day 2 , day 7 day 28 . 2 . Measurement blood flow select suitable patient 3 . 10 minute questionnaire discharge visit day 28 .</brief_summary>
	<brief_title>Anti Ischemic Effects Abciximab Angioplasty Stenting Patients</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>1 . Have either : clinical history anginal symptom positive stress test stent restenosis 2 . Have angiographic &gt; 70 % coronary artery stenosis treat coronary angioplasty stenting procedure 3 . For least four week prior procedure , Hmgcoa reductase inhibitor stable statin dose 4. negative pregnancy test 5. able give inform consent 1 . Coronary intervention within four week prior enrollment . 2 . Treatment abciximab antagonist within four week . 3. treatment thrombolytic therapy within 48 hour 4 . MI within 2 month . 5. recent infection 6. general anesthesia within 3 month . 7. renal failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>